Neurodegeneration: Linking ubiquitin/proteasome pathway impairment with inflammation

International Journal of Biochemistry and Cell Biology

Volumn 35, Issue 5, 2003, Pages 547-552

  Li, Zongmin ^a   Jansen, Marlon ^a   Pierre, Sha Ron ^a   Figueiredo Pereira, Maria E ^a  

^a CITY UNIVERSITY OF NEW YORK   (United States)

Author keywords

Inflammation; Neurodegeneration; Ubiquitin proteasome pathway

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; CADMIUM; CELECOXIB; CHAPERONE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; IBUPROFEN; INDOMETACIN; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E2; PROSTAGLANDIN J2; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN; SULINDAC SULFIDE; UBIQUITIN;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; CELL INCLUSION; DEGENERATIVE DISEASE; ENZYME INDUCTION; ENZYME INHIBITION; ENZYME MECHANISM; ENZYME SYNTHESIS; HUMAN; INFLAMMATION; MUSCULAR DYSTROPHY; NERVE CELL CULTURE; NERVE DEGENERATION; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PROTEIN AGGREGATION; PROTEIN EXPRESSION; REVIEW; UPREGULATION;

EID: 0037401694     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1357-2725(02)00384-9     Document Type: Review

References (42)

1. Auluck P.K., Chan H.Y., Trojanowski J.Q., Lee V.M., Bonini N.M. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science. 295:2002;865-868.
2. Bence N.F., Sampat R.M., Kopito R.R. Impairment of the ubiquitin-proteasome system by protein aggregation. Science. 292:2001;1552-1555.
3. Carrard G., Bulteau A., Petropoulos I., Friguet B. Impairment of proteasome structure and function in aging. International Journal of Biochemistry and Cell Biology. 34:2002;1461.
4. Chan H.Y., Warrick J.M., Gray-Board Paulson H.L., Bonini N.M. Mechanisms of chaperone suppression of polyglutamine disease: Selectivity, synergy and modulation of protein solubility in Drosophila. Human Molecular Genetics. 9:2000;2811-2820.
5. Chen C., Magee J.C., Bazan N.G. Cyclooxygenase-2 regulates prostaglandin e(2) signaling in hippocampal long-term synaptic plasticity. Journal of Neurophysiology. 87:2002;2851-2857.
6. Evert B.O., Vogt I.R., Kindermann C., Ozimek L., de Vos R.A., Brunt E.R., Schmitt I., Klockgether T., Wullner U. Inflammatory genes are upregulated in expanded ataxin-3-expressing cell lines and spinocerebellar ataxia type 3 brains. Journal of Neuroscience. 21:2001;5389-5396.
7. Figueiredo-Pereira M.E., Li Z., Jansen M., Rockwell P. N-Acetylcysteine and celecoxib lessen cadmium cytotoxicity which is associated with cyclooxygenase-2 up-regulation in mouse neuronal cells. Journal of Biology Chemistry. 277:2002;25283-25289.
8. Figueiredo-Pereira, M. E., & Rockwell, P. (2001). The ubiquitin/proteasome pathway in neurological disorders. In N. L. Banik, A. Lajtha, & M. Smith (Eds.), Proteolysis in the pathophysiology of neurodegenerative disease. New York, NY: Plenum.
9. Hastings T.G. Enzymatic oxidation of dopamine: The role of prostaglandin H synthase. Journal of Neurochemistry. 64:1995;919-924.
10. Ho L., Pieroni C., Winger D., Purohit D.P., Aisen P.S., Pasinetti G.M. Regional distribution of cyclooxygenase-2 in the hippocampal formation in Alzheimer's disease. Journal of Neuroscience Research. 57:1999;295-303.
11. Hylander B.L., Chen X., Graf P.C., Subjeck J.R. The distribution and localization of HSP110 in brain. Brain Research. 869:2000;49-55.
12. Kaufmann W.E., Worley P.F., Pegg J., Bremer M., Isakson P. COX-2, a synaptically induced enzyme, is expressed by excitatory neurons at postsynaptic sites in rat cerebral cortex. Proceedings of the National Academy of Sciences of the United States of America. 93:1996;2317-2321.
13. Kondo M., Oya-Ito T., Kumagai T., Osawa T., Uchida K. Cyclopentenone prostaglandins as potential inducers of intracellular oxidative stress. The Journal of Biological Chemistry. 276:2001;12076-12083.
14. Kulkarni S.K., Jain N.K., Singh A. Cyclooxygenase isoenzymes and newer therapeutic potential for selective COX-2 inhibitors. Methods and Findings in Experimental and Clinical Pharmacology. 22:2000;291-298.
15. Li, Z., Fanara, P., Melandri, F., Jansen, M., Hunter, L., Wright, S., Valbrun, D., & Figueiredo-Pereira, M. E. (2002). Protaglandin J2 inhibits the ubiquitin hydrolase UCH-L1 and exerts a positive feedback on cyclooxygenase 2 expression in neuronal cells: A putative role in neurodegeneration? Manuscript submitted for publication.
16. Lowe J., Mayer J., Landon M., Layfield R. Ubiquitin and the molecular pathology of neurodegenerative diseases. Adv. Exp. Med. Biol. 487:2001;169-186.
17. Martinez M., Martinez N., Hernandez A.I., Ferrandiz M.L. Hypothesis: Can N-acetylcysteine be beneficial in Parkinson's disease? Life Sci. 64:1999;1253-1257.
18. Masferrer J.L., Zweifel B.S., Colburn S.M., Ornberg R.L., Salvemini D., Isakson P., Seibert K. The Role of Cyclooxygenase-2 in Inflammation. American Journal of Therapeutics. 2:1995;607-610.
19. Mattammal M.B., Strong R., Lakshmi V.M., Chung H.D., Stephenson A.H. Prostaglandin H synthetase-mediated metabolism of dopamine: Implication for Parkinson's disease. Journal of Neurochemistry. 64:1995;1645-1654.
20. Mezey E., Dehejia A., Harta G., Papp M.I., Polymeropoulos M.H., Brownstein M.J. Alpha synuclein in neurodegenerative disorders: Murderer or accomplice? Nature Medicine. 4:1998;755-757. (in process citation).
21. Mullally J.E., Moos P.J., Edes K., Fitzpatrick F.A. Cyclopentenone prostaglandins of the J series inhibit the ubiquitin isopeptidase activity of the proteasome pathway. The Journal of Biological Chemistry. 276:2001;30366-30373.
22. Nagata A., Suzuki Y., Igarashi M., Eguchi N., Toh H., Urade Y., Hayaishi O. Human brain prostaglandin D synthase has been evolutionarily differentiated from lipophilic-ligand carrier proteins. Proceedings of the National Academy of Sciences of the United States of America. 88:1991;4020-4024.
23. Oka A., Itoh M., Takashima S. The early induction of cyclooxygenase 2 associated with neurofibrillary degeneration in brains of patients with Fukuyama-type congenital muscular dystrophy. Neuropediatrics. 30:1999;34-37.
24. Oka A., Takashima S. Induction of cyclo-oxygenase 2 in brains of patients with Down's syndrome and dementia of Alzheimer type: Specific localization in affected neurones and axons. Neuroreport. 8:1997;1161-1164.
25. Pasinetti G.M., Aisen P.S. Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain. Neuroscience. 87:1998;319-324.
26. Prasad K.N., La Rosa F.G., Prasad J.E. Prostaglandins act as neurotoxin for differentiated neuroblastoma cells in culture and increase levels of ubiquitin and beta-amyloid. In Vitro Cellular and Developmental Biology: Animal. 34:1998;265-274.
27. Rockwell P., Yuan H., Magnusson R., Figueiredo-Pereira M.E. Proteasome inhibition in neuronal cells induces a proinflammatory response manifested by upregulation of cyclooxygenase-2 its accumulation as ubiquitin conjugates, and production of the prostaglandin PGE(2). Archives of Biochemistry and Biophysics. 374:2000;325-333.
28. Sairanen T., Ristimaki A., Karjalainen-Lindsberg M.L., Paetau A., Kaste M., Lindsberg P.J. Cyclooxygenase-2 is induced globally in infarcted human brain. Annals of Neurology. 43:1998;738-747.
29. Shen X.M., Li H., Dryhurst G. Oxidative metabolites of 5-S-cysteinyldopamine inhibit the alpha-ketoglutarate dehydrogenase complex: Possible relevance to the pathogenesis of Parkinson's disease. Journal of Neural Transmission. 107:2000;959-978.
30. Sherman M.Y., Goldberg A.L. Cellular defenses against unfolded proteins: A cell biologist thinks about neurodegenerative diseases. Neuron. 29:2001;15-32.
31. Shringarpure R., Davies K.J. Protein turnover by the proteasome in aging and disease(1,2). Free Radical Biology Medicine. 32:2002;1084-1089.
32. Smith W.L., De Witt D.L., Garavito R.M. Cyclooxygenases: Structural, cellular, and molecular biology. Annual Review of Biochemistry. 69:2000;145-182.
33. Stewart W.F., Kawas C., Corrada M., Metter E.J. Risk of Alzheimer's disease and duration of NSAID use. Neurology. 48:1997;626-632. (see comments).
34. Straus D.S., Glass C.K. Cyclopentenone prostaglandins: New insights on biological activities and cellular targets. Med. Res. Rev. 21:2001;185-210.
35. Taylor J.P., Hardy J., Fischbeck K.H. Toxic proteins in neurodegenerative disease. Science. 296:2002;1991-1995.
36. Teismann P., Ferger B. Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease. Synapse. 39:2001;167-174.
37. Urade Y., Hayaishi O. Prostaglandin D2 and sleep regulation. Biochimica et Biophysica Acta. 1436:1999;606-615.
38. Weggen S., Eriksen J.L., Das P., Sagi S.A., Wang R., Pietrzik C.U., Findlay K.A., Smith T.E., Murphy M.P., Bulter T., Kang D.E., Marquez-Sterling N., Golde T.E., Koo E.H. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature. 414:2001;212-216.
39. Wyss-Coray T., Mucke L. Inflammation in neurodegenerative disease - a double-edged sword. Neuron. 35:2002;419-432.
40. Yamagata K., Andreasson K.I., Kaufmann W.E., Barnes C.A., Worley P.F. Expression of a mitogen-inducible cyclooxygenase in brain neurons: Regulation by synaptic activity and glucocorticoids. Neuron. 11:1993;371-386.
41. Yasojima K., Tourtellotte W.W., McGeer E.G., McGeer P.L. Marked increase in cyclooxygenase-2 in ALS spinal cord: Implications for therapy. Neurology. 57:2001;952-956.
42. Zandi P.P., Anthony J.C., Hayden K.M., Mehta K., Mayer L., Breitner J.C. Reduced incidence of AD with NSAID but not H(2) receptor antagonists: The Cache County Study. Neurology. 59:2002;880-886.